Q3 EPS Estimates for Kura Oncology Cut by Leerink Partnrs

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Leerink Partnrs lowered their Q3 2025 EPS estimates for Kura Oncology in a report issued on Wednesday, May 14th. Leerink Partnrs analyst J. Chang now expects that the company will post earnings of $0.15 per share for the quarter, down from their prior estimate of $0.16. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share. Leerink Partnrs also issued estimates for Kura Oncology's Q4 2025 earnings at $0.18 EPS, FY2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.69) EPS.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million.

Other equities analysts also recently issued reports about the stock. Cantor Fitzgerald raised shares of Kura Oncology to a "strong-buy" rating in a research note on Tuesday, March 4th. Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. Barclays decreased their price target on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Finally, Wall Street Zen cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and a consensus price target of $24.50.

Kura Oncology Trading Down 9.6%

KURA stock traded down $0.60 during trading on Monday, reaching $5.64. The company had a trading volume of 2,677,684 shares, compared to its average volume of 1,194,809. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $23.48. The company has a market cap of $488.28 million, a P/E ratio of -2.39 and a beta of 0.50. The business has a 50 day moving average of $6.30 and a 200 day moving average of $8.45. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in KURA. Barclays PLC lifted its stake in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after buying an additional 84,563 shares in the last quarter. SG Americas Securities LLC bought a new position in Kura Oncology during the fourth quarter valued at approximately $436,000. Moody Aldrich Partners LLC lifted its position in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock valued at $1,251,000 after purchasing an additional 42,712 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in Kura Oncology by 11.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company's stock valued at $144,000 after purchasing an additional 1,750 shares during the period. Finally, Jennison Associates LLC bought a new position in Kura Oncology during the fourth quarter valued at approximately $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.